PLG0206 has the potential to be the first approved therapy specifically indicated for the treatment of periprosthetic joint infection
PITTSBURGH--(BUSINESS WIRE)--Peptilogics, a biotech company engineering peptide therapeutics to improve the treatment landscape for patients with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s lead drug candidate, PLG0206, for the treatment of periprosthetic joint infection (PJI).
“Total joint replacements are the most common major surgical procedure performed annually across the globe. At any time following surgery, patients can develop PJI, a devastating and life-threatening condition with suboptimal treatment options and a high mortality rate,” said David Huang, M.D., Ph.D., Chief Medical Officer of Peptilogics. “Receiving the FDA’s Fast Track designation supports our efforts to improve the standard of care for those impacted by PJI. We look forward to continuing to evaluate PLG0206’s potential to address the unique challenges of the disease and help patients in need.”